Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELVN Enliven Therapeutics	$21.50 +1.6%	$19.03	$13.30 ▼ $30.03	$1.04B	0.79	294,544 shs	485,100 shs
PTCT PTC Therapeutics	$48.89 -1.5%	$48.14	$28.72 ▼ $58.38	$3.93B	0.51	867,998 shs	1.03 million shs
RNA Avidity Biosciences	$29.90 +0.1%	$30.65	$21.51 ▼ $56.00	$3.60B	0.95	1.39 million shs	815,429 shs
SRPT Sarepta Therapeutics	$17.46 -8.0%	$40.94	$17.00 ▼ $162.95	$1.87B	0.61	2.11 million shs	10.73 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELVN Enliven Therapeutics	+4.29%	-2.94%	+29.02%	+2.82%	-3.11%
PTCT PTC Therapeutics	+0.04%	-2.42%	+8.03%	-10.29%	+38.72%
RNA Avidity Biosciences	+2.47%	+1.74%	-2.32%	-6.80%	-24.68%
SRPT Sarepta Therapeutics	+0.58%	-11.97%	-49.92%	-73.96%	-88.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELVN Enliven Therapeutics	2.6581 of 5 stars	3.5	1.0	0.0	3.0	4.2	0.0
PTCT PTC Therapeutics	4.6661 of 5 stars	4.3	4.0	4.4	1.8	0.8	1.3
RNA Avidity Biosciences	2.3515 of 5 stars	4.5	0.0	0.0	3.2	0.8	0.0
SRPT Sarepta Therapeutics	4.5826 of 5 stars	4.2	2.0	4.2	1.6	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELVN Enliven Therapeutics	3.00	Buy	$39.60	84.19% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	32.95% Upside
RNA Avidity Biosciences	3.06	Buy	$65.59	119.36% Upside
SRPT Sarepta Therapeutics	2.44	Hold	$60.88	248.65% Upside

Current Analyst Ratings Breakdown

Latest ELVN, PTCT, SRPT, and RNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
6/24/2025	RNA Avidity Biosciences	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
6/17/2025	RNA Avidity Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
6/17/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$50.00 ➝ $25.00
6/17/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$29.00
6/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $30.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
PTCT PTC Therapeutics	$806.78M	4.80	N/A	N/A	($14.24) per share	-3.43
RNA Avidity Biosciences	$10.90M	330.60	N/A	N/A	$11.94 per share	2.50
SRPT Sarepta Therapeutics	$1.90B	0.90	$2.24 per share	7.79	$15.99 per share	1.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.51	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.60	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)

Latest ELVN, PTCT, SRPT, and RNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELVN Enliven Therapeutics	N/A	21.07	21.06
PTCT PTC Therapeutics	N/A	3.89	3.85
RNA Avidity Biosciences	N/A	16.91	16.91
SRPT Sarepta Therapeutics	1.00	4.02	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELVN Enliven Therapeutics	95.08%
PTCT PTC Therapeutics	N/A
RNA Avidity Biosciences	N/A
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
ELVN Enliven Therapeutics	25.90%
PTCT PTC Therapeutics	5.50%
RNA Avidity Biosciences	3.83%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable

ELVN, PTCT, SRPT, and RNA Headlines

Recent News About These Companies

Sarepta Therapeutics Is Already Down 84% This Year. And The Other Shoe Just Dropped.

June 25 at 3:01 PM | investors.com

Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny

June 25 at 2:06 PM | benzinga.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 5.7% - Should You Sell?

June 25 at 12:13 PM | marketbeat.com

FDA investigates patient deaths after treatment with Sarepta's Duchenne gene therapy Elevidys

June 25 at 12:11 PM | fiercepharma.comF

1SRPT : Assessing Sarepta Therapeutics: Insights From 38 Financial Analysts

June 25 at 12:11 PM | benzinga.com

This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

June 25 at 10:38 AM | benzinga.com

HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT)

June 25 at 8:22 AM | marketbeat.com

Five things: Beth Israel DEI, Hao's successor, Sarepta investigation, and welcome back, Lucy

June 25 at 7:10 AM | bizjournals.com

Sell Rating for Sarepta Therapeutics Amid FDA Investigation and Valuation Concerns

June 25 at 6:25 AM | tipranks.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of "Hold" by Brokerages

June 25 at 2:23 AM | americanbankingnews.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Brokerages

June 25 at 2:20 AM | marketbeat.com

FDA investigates patient deaths after treatment with Sarepta's gene therapy

June 24 at 5:04 PM | reuters.com

Sarepta and Roche halt DMD gene therapy’s use in certain patients after second death

June 24 at 4:08 PM | pharmaceutical-technology.comP

Sarepta Viral Vector Gets FDA Platform Technology Designation

June 24 at 4:08 PM | msn.com

Sarepta Therapeutics (SRPT) Tumbles 44% W/W as Analyst Cuts Price Target by 63%

June 24 at 11:30 AM | insidermonkey.com

SRPT STOCK LOSS: Sarepta Therapeutics, Inc. Shareholders are Alerted of Ongoing Securities Fraud Investigation -- Contact BFA Law (NASDAQ:SRPT)

June 24 at 8:18 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 23 at 11:53 AM | globenewswire.com

SRPT FRAUD ALERT: Sarepta Therapeutics, Inc. ...

June 22 at 10:00 AM | gurufocus.com

SRPT FRAUD ALERT: Sarepta Therapeutics, Inc. Investors are Reminded of Ongoing Securities Fraud Investigation -- Contact BFA Law (NASDAQ:SRPT)

June 22 at 9:33 AM | globenewswire.com

Sarepta Therapeutics (NASDAQ:SRPT) Earns "Market Perform" Rating from William Blair

June 22 at 2:13 AM | americanbankingnews.com

Sarepta Therapeutics (SRPT) Faces Setback Amid Gene Therapy Concerns

June 21, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN, PTCT, SRPT, and RNA Company Descriptions

Enliven Therapeutics NASDAQ:ELVN

$21.50 +0.34 (+1.61%)

Closing price 04:00 PM Eastern

Extended Trading

$21.51 +0.01 (+0.05%)

As of 04:08 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

PTC Therapeutics NASDAQ:PTCT

$48.89 -0.73 (-1.47%)

Closing price 04:00 PM Eastern

Extended Trading

$48.88 -0.01 (-0.02%)

As of 04:04 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Avidity Biosciences NASDAQ:RNA

$29.90 +0.03 (+0.10%)

Closing price 04:00 PM Eastern

Extended Trading

$30.11 +0.21 (+0.70%)

As of 07:41 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Sarepta Therapeutics NASDAQ:SRPT

$17.46 -1.52 (-8.01%)

Closing price 04:00 PM Eastern

Extended Trading

$17.65 +0.19 (+1.09%)

As of 07:58 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time